Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
28/04/2020
TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
28/04/2020
TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
28/04/2020
TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
28/04/2020
TA513: Obinutuzumab for untreated advanced follicular lymphoma
28/04/2020
TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
28/04/2020
TA534: Dupilumab for treating moderate to severe atopic dermatitis
28/04/2020
TA521: Guselkumab for treating moderate to severe plaque psoriasis
28/04/2020
TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
28/04/2020
TA546: Padeliporfin for untreated localised prostate cancer
28/04/2020
TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
28/04/2020
TA565: Benralizumab for treating severe eosinophilic asthma
28/04/2020
TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
28/04/2020
TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
28/04/2020
TA585: Ocrelizumab for treating primary progressive multiple sclerosis
28/04/2020
TA542: Cabozantinib for untreated advanced renal cell carcinoma
28/04/2020
TA523: Midostaurin for untreated acute myeloid leukaemia
28/04/2020
TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
28/04/2020
TA623: Patiromer for treating hyperkalaemia
28/04/2020
TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
23/04/2020
TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
8
9
10
11
12
13
14
15
16
17
18
Follow AWTTC: